In This Article:
Global medical technology company BD has entered into a strategic partnership with Ypsomed, an injection systems manufacturer, to advance self-injection solutions specifically designed for high-viscosity biologic drugs.
The collaboration focuses on integrating BD's Neopak XtraFlow glass prefillable syringe with Ypsomed’s YpsoMate 2.25 autoinjector platform to address the current challenges of delivering biologic drugs that have a higher viscosity (thickness) of more than 15 centipoise.
The BD Neopak XtraFlow Glass Prefillable Syringe is the latest addition to BD's portfolio, having an 8mm needle and a thinner wall cannula that improves the subcutaneous delivery of biologics with higher viscosity profiles.
This advancement aims to push the boundaries of flow and usability, surpassing the capabilities of standard half-inch needles.
Ypsomed will expand its YpsoMate 2.25 autoinjector platform to accommodate BD's new syringe format.
Adjustments will be made for the shorter needle, alongside tooling and assembly qualification and comprehensive technical testing to ensure device reliability.
The YpsoMate autoinjector is designed for ease of use, allowing individuals with limited grip strength or vision to administer their medication safely and effortlessly.
Ypsomed Delivery Systems chief business officer Ulrike Bauer said: “We are excited to welcome the first pharmaceutical customers to experience the benefits of the BD Neopak XtraFlow glass prefillable syringe with the YpsoMate 2.25 autoinjector.”
BD Pharmaceutical Systems worldwide president Patrick Jeukenne said: “Cross-supplier collaborations are vital in today’s pharmaceutical ecosystem.
“These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster.”
In August 2024, Astria Therapeutics selected Ypsomed’s Ypsomate autoinjector as its partner for the administration of STAR-0215 for the treatment of hereditary angioedema.
"Ypsomed and BD to enhance high-viscosity drug delivery " was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.